Pipeline

September 24, 2018

Company	Drug/Device	Medical Condition	Status
inui™ Health	In-home urine analysis platform, which includes a disposable test and smart phone app (iOS and Android)	Kidney function, metabolic disorders and urinary tract infections (UTI)	Granted 510(k) clearance and a Clinical Laboratory Improvements Amendments (CLIA) waiver by the FDA CE Mark certification
Camurus	CAM2038	Chronic low back pain	Met primary and first secondary endpoints; resulted in significantly improved relief of the average and worst pain intensity compared to placebo
Iterum Therapeutics plc	Sulopenem	Gram-negative, multi-drug resistant infections	Initiated SURE 2 and SURE 3 Phase III clinical trials
AstraZeneca Pharmaceuticals LP	FASENRA™ (benralizumab)	Severe eosinophilic asthma	Phase III extension BORA trial results show long-term safety and efficacy as an add-on maintenance treatment
Regeneron Pharmaceuticals, Inc. and Sanofi	Dupixent® (dupilumab) mono-therapy	moderate-to-severe atopic dermatitis	Phase III trial demonstrated a significant improvement in signs and symptoms
Alnylam Pharmaceuticals, Inc.	Patisiran	Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults	APOLLO Phase III trial showed improved markers of cardiomyopathy
AstraZeneca	Triple combination therapy PT010	COPD	Seeking FDA approval after Phase III trial found it outperformed its dual-therapy rivals eight of nine times
Teva Pharmaceutical Industries	Ajovy (fremanezumab)	Migraine	Granted approval by the FDA
Venture Heat®	Infrared Heat Therapy using Far infrared Rays (FIR)	Pain	Granted approval by the FDA
Sebacia, Inc.	Sebacia Microparticles	Mild to moderate inflammatory acne vulgaris	Granted clearance by the FDA
WAT Medical	HeadaTerm	Migraine	Granted clearance by the FDA
AstraZeneca	Lumoxiti (moxetumomab pasudotox-tdfk)	Adults with relapsed or refractory hairy cell leukemia (HCL) who have had at least two previous therapies	Granted clearance by the FDA
Ironwood Pharmaceuticals, Inc.	Praliciguat (IW-1973)	Heart failure	Granted Fast Track designation by the FDA
Genentech	Subcutaneous (SC) formulation of Actemra® (tocilizumab)	Active systemic juvenile idiopathic arthritis (SJIA) in patients two year and up	Granted approval by the FDA
STAAR Surgical Company	PMA Supplement for the Visian Toric ICL	Myopia with astigmatism	Granted approval by the FDA